INVO Bioscience, Inc. (NASDAQ:INVO) Short Interest Update

INVO Bioscience, Inc. (NASDAQ:INVO) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 75,600 shares, a growth of 144.7% from the May 31st total of 30,900 shares. Currently, 2.0% of the shares of the stock are sold short. Based on an average daily volume of 3,800,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On INVO Bioscience

An institutional investor recently bought a new position in INVO Bioscience stock. Sabby Management LLC bought a new stake in INVO Bioscience, Inc. (NASDAQ:INVO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 231,023 shares of the company’s stock, valued at approximately $183,000. INVO Bioscience comprises about 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 29th biggest position. Sabby Management LLC owned approximately 9.43% of INVO Bioscience at the end of the most recent reporting period. 12.02% of the stock is owned by institutional investors and hedge funds.

INVO Bioscience Trading Down 3.3 %

Shares of INVO Bioscience stock opened at $0.84 on Friday. The company has a current ratio of 0.19, a quick ratio of 0.16 and a debt-to-equity ratio of 2.94. The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.03. INVO Bioscience has a 12-month low of $0.50 and a 12-month high of $7.20.

INVO Bioscience (NASDAQ:INVO) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.42) EPS for the quarter. The business had revenue of $1.58 million for the quarter.

INVO Bioscience Company Profile

INVO Bioscience, Inc, together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.